Multi-targeted RNAi Therapeutic for Treatment of Breast Cancer

多靶点 RNAi 治疗乳腺癌

• 批准号: 7612580
• 负责人: Patrick Y Lu
• 金额: $ 22.8万
• 依托单位: SIRNAOMICS, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-22 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7612580
• 关键词: Adjuvant Therapy; Animal Model; Antisense Oligonucleotides; Avastin; Binding; Biological Models; Breast; Breast Cancer Cell; Breast Cancer Treatment; Cancer Death Rates; Cancer Etiology; Cells; Cessation of life; Cleaved cell; Clinical; Clinical Trials; Complex; Cultured Cells; Detection; Development; Disease; Disease model; Dose; Double-Stranded RNA; Drug Industry; EGFR gene; Early Diagnosis; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor Receptor; Gene Silencing; Gene Targeting; Genes; Growth; Head and Neck Cancer; Head and Neck Neoplasms; High Dose Chemotherapy; Histidine; Human; Individual; Keratitis; Life; Lysine; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of lung; Mediating; Messenger RNA; Modeling; Monoclonal Antibodies; Mus; Nucleotides; Operative Surgical Procedures; Outcome; Pathway interactions; Patients; Polymers; Proteins; Public Health; RNA Interference; RNA-Induced Silencing Complex; Radiation therapy; Reverse Transcriptase Polymerase Chain Reaction; Ribonuclease III; Role; Sentinel Lymph Node Biopsy; Small Interfering RNA; Standards of Weights and Measures; Stem cell transplant; Technology; Testing; Therapeutic; Therapeutic Intervention; Treatment Protocols; Tumor Angiogenesis; Tyrosine Kinase Inhibitor; Vascular Endothelial Growth Factors; Woman; Xenograft Model; antiangiogenesis therapy; c-erbB-1 Proto-Oncogenes; chemotherapy; clinical effect; day; dosage; endonuclease; hormone therapy; human DICER1 protein; human FRAP1 protein; in vivo; inhibitor/antagonist; malignant breast neoplasm; nuclease; ocular angiogenesis; response; single molecule; success; therapeutic target; time interval; tumor; tumor growth; tumor xenograft

DESCRIPTION (provided by applicant): Millions of women have been treated for or are living with breast cancer, and tens of thousands of women are expected to die from the disease each year. As breast cancer disease remains the second leading cause of cancer death in women (after lung cancer), different types of treatment have been developed including surgery, radiation therapy, chemotherapy and hormone therapy. New types of therapies are also going through development and trials in order to treat this malignant disease. This proposal is to use the breakthrough RNAi technology to develop a multi-targeted therapeutics to treat breast cancer. This proposed study is to take advantage of the HKP carriers with siRNA cocktails targeting three specific genes (EGFR, Raf-1 and mTOR) as an RNAi therapeutic protocol for treatment of breast cancer, and to combine the siRNA cocktail with Avastin to mimic a clinical regimen. The success of this approach will have tremendous scientific and therapeutic impacts for combating breast cancer and many other cancers. PUBLIC HEALTH RELEVANCE: As breast cancer disease remains the second leading cause of cancer death in women (after lung cancer), various types of treatment have been developed including surgery, radiation therapy, chemotherapy and hormone therapy. Using the breakthrough RNAi technology, we are developing a multi-targeted therapeutics to treat breast cancer. This proposed study is to take advantage of the HKP carriers with siRNA cocktails targeting three specific genes as an RNAi therapeutic protocol for treatment of breast cancer, and to combine the siRNA cocktail with Avastin to mimic a clinical regimen. The outcome of the project is expected to be of significant value for the patients and pharmaceutical industry.

描述（由申请人提供）：数以百万计的女性已经接受乳腺癌治疗或患有乳腺癌，预计每年有数万名女性死于该疾病。由于乳腺癌疾病仍然是女性癌症死亡的第二大原因（仅次于肺癌），因此已经开发了不同类型的治疗方法，包括手术、放射治疗、化疗和激素治疗。为了治疗这种恶性疾病，新型疗法也正在进行开发和试验。该提案旨在利用突破性的RNAi技术来开发治疗乳腺癌的多靶点疗法。这项拟议的研究是利用 HKP 载体和针对三种特定基因（EGFR、Raf-1 和 mTOR）的 siRNA 鸡尾酒作为治疗乳腺癌的 RNAi 治疗方案，并将 siRNA 鸡尾酒与阿瓦斯汀结合起来模拟临床养生法。这种方法的成功将对对抗乳腺癌和许多其他癌症产生巨大的科学和治疗影响。公共卫生相关性：由于乳腺癌疾病仍然是女性癌症死亡的第二大原因（仅次于肺癌），因此已经开发了各种类型的治疗方法，包括手术、放射治疗、化疗和激素治疗。利用突破性的 RNAi 技术，我们正在开发一种治疗乳腺癌的多靶点疗法。这项拟议的研究是利用 HKP 载体和针对三种特定基因的 siRNA 鸡尾酒作为治疗乳腺癌的 RNAi 治疗方案，并将 siRNA 鸡尾酒与阿瓦斯汀结合起来模拟临床方案。该项目的成果预计将对患者和制药行业产生重大价值。